Last reviewed 2026-04-20 · How we verify

Ipradol (HEXOPRENALINE)

Phase 2 active Small molecule

Ipradol (generic name: HEXOPRENALINE) is a hexoprenaline drug. It is currently in Phase 2 development.

Ipradol works by stimulating beta-adrenergic receptors in the body, which can increase heart rate and blood pressure.

Ipradol, also known as hexoprenaline, is a small molecule drug in the hexoprenaline class. Its exact target and mechanism of action are unknown, but it is believed to work as a beta-adrenergic agonist. Ipradol's commercial status and approved indications are unclear, and it is not known whether it is patented or available as a generic. Further research is needed to determine its safety profile and potential uses. As a result, Ipradol is not widely recognized or used in clinical practice.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	HEXOPRENALINE
Drug class	hexoprenaline
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Imagine your body's 'fight or flight' response, where your heart beats faster and your blood pressure rises to help you react quickly to a threat. Ipradol triggers this response by binding to special receptors on the surface of cells, which sends a signal to increase heart rate and blood pressure. This can be helpful in certain medical situations, but it can also have negative effects if not used carefully.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ipradol CI brief — competitive landscape report
Ipradol updates RSS · CI watch RSS

Frequently asked questions about Ipradol

What is Ipradol?

Ipradol (HEXOPRENALINE) is a hexoprenaline drug.

How does Ipradol work?

Ipradol works by stimulating beta-adrenergic receptors in the body, which can increase heart rate and blood pressure.

What is the generic name of Ipradol?

HEXOPRENALINE is the generic (nonproprietary) name of Ipradol.

What drug class is Ipradol in?

Ipradol belongs to the hexoprenaline class. See all hexoprenaline drugs at /class/hexoprenaline.

What development phase is Ipradol in?

Ipradol is in Phase 2.

Drug class: All hexoprenaline drugs
Therapeutic area: All drugs in Cardiovascular

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing